Background and aims: Minimisation of the placebo responses in randomised controlled trials [RCTs] is essential for efficient evaluation of new interventions. Placebo rates have been high in ulcerative colitis [UC] clinical trials, and factors influencing this are poorly understood. We quantify placebo response and remission rates in UC RCTs and identify trial design factors influencing them.


Anti-Inflammatory Agents Non-Steroidal, DAI, Disease Activity Index, Drug Therapy, Immunosuppressive Agents, Induction Chemotherapy, Maintenance Therapy, Mayo Clinic Score, MCS, Placebo Effect, Randomised controlled trial, RCT, therapeutic use, Treatment Outcome, Ulcerative Colitis

Read More